Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

BPGbio CEO Dr. Niven R. Narain Named to The Medicine Maker Power List 2025

BOSTON, April 28, 2025 (GLOBE NEWSWIRE) -- BPGbio, Inc., a biology-first, AI-powered clinical-stage biopharma company, today announced that President and CEO Niven R. Narain, Ph.D. has been named to The Medicine Maker’s Power List 2025. The annual list celebrates researchers, entrepreneurs, and industry leaders driving meaningful progress in drug development and manufacturing, spotlighting individuals whose work is shaping the future of human health.

Selected in the bioprocessing category, Dr. Narain is honored for his pioneering work at the intersection of biology, AI, and translational medicine. Under his leadership, BPGbio has focused on advancing a patient-centric approach to drug development, using biological data and causal AI modeling to inform discovery and development decisions in over 15 disease models. At the center of this approach is the company’s proprietary NAi Interrogative Biology® Platform, which uses Bayesian AI to analyze complex multi-omic data and uncover new therapeutic and diagnostic opportunities.

“Niven is a true visionary who has dedicated his career to reimagining how we understand and treat the patient, not just the disease,” said Chas Bountra, Ph.D., Chairman of the Scientific Advisory Board of BPGbio, and the Pro-Vice Chancellor for Innovation at the University of Oxford. “By combining biology, AI, and real patient data, he’s created a foundation for a smarter, faster, and more precise future in drug discovery.”

As a clinical scientist and biotech entrepreneur, Narain co-founded BPGbio after leaving academic medicine with the goal of accelerating innovation for patients. His work has led to more than 100 drug and diagnostic candidates, including BPM31510, currently in phase 2 clinical trials for glioblastoma, and in phase 2/3 planning phase for pancreatic cancer, and rare diseases like Primary CoQ10 Deficiency and epidermolysis bullosa (EB), among other emerging lead molecules primed for Phase 1 studies.

Dr. Narain’s inclusion on this year’s Power List reflects his ongoing commitment to transforming drug discovery through data-driven, biology-first innovation. The full Power List 2025 is available now at themedicinemaker.com.

About BPGbio

BPGbio is a leading biology-first AI-powered clinical stage biopharma focused on mitochondrial biology and protein homeostasis. The company has a deep pipeline of AI-developed therapeutics spanning oncology, rare disease and neurology, including several in late-stage clinical trials. BPGbio’s novel approach is underpinned by NAi, its proprietary Interrogative Biology Platform, protected by over 400 US and international patents; one of the world’s largest clinically annotated non-governmental biobanks with longitudinal samples; and exclusive access to the most powerful supercomputer in the world. With these tools, BPGbio is redefining how patient biology can be modeled using bespoke Bayesian AI specifically designed for solving large-scale biology challenges. Headquartered in greater Boston, the company is at the forefront of a new era in medicine, combining biology, multi-modal data, and AI to transform the way we understand, diagnose, and treat disease. For more information, visit www.bpgbio.com.

Media Contact: media@bpgbio.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/63efeca9-67af-4af2-9e52-9533b8c59e5b


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.